Stories
Slash Boxes
Comments

SoylentNews is people

SoylentNews is powered by your submissions, so send in your scoop. Only 18 submissions in the queue.
posted by janrinok on Thursday June 23, @09:09AM   Printer-friendly

US Supreme Court rejects Bayer's bid to end Roundup lawsuits:

The US Supreme Court has rejected Bayer's bid to dismiss legal claims by customers who say its weedkiller causes cancer, as the German company seeks to avoid potentially billions of dollars in damages.

The justices turned away a Bayer appeal's on Tuesday and left in place a lower court decision that upheld $25m in damages awarded to California resident Edwin Hardeman, a user of its product Roundup, who blamed his cancer on the pharmaceutical and chemical giant's glyphosate-based weedkillers.

The Supreme Court's ruling dealt a blow to Bayer as the company manoeuvres to limit its legal liability in thousands of cases. The justices have a second Bayer petition pending on a related issue that they could act upon in the coming weeks.

Roundup-related lawsuits have dogged Bayer since it acquired the brand as part of its $63bn purchase of agricultural seeds and pesticides maker Monsanto in 2018.

[...] The lawsuits against Bayer have said the company should have warned customers of the alleged cancer risk.

[...] Bayer plans to replace glyphosate in weedkillers for the US residential market of non-professional gardeners with other active ingredients.


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by JoeMerchant on Thursday June 23, @06:52PM

    by JoeMerchant (3937) on Thursday June 23, @06:52PM (#1255645)

    >amplified the toxic effect on human cells—even at concentrations much more diluted than those used on farms and lawns.

    This is something that most people gloss over, and it's a huge factor in bio-availability and potency of drugs, toxins, etc.

    There is a great drug: Nuedexta that is a simple combination of dextromethorphan and qunindine. By itself, dextromethorphan is too weak and short acting to be a practical treatment for PBA, but the quinidine makes the dex dwell in the brain much longer, and two pills a day give significant control over unwanted impulses.

    I worked with some holier than thou academic researchers who were 100% convinced that adding a GRAS component to a drug would be a zero effort approval for the new compound as part of their compliance system - breathe into a cheapo mass spectrometer which can detect the presence/absence of the GRAS component, becomes "proof" that the drug/medication was ingested and absorbed. I, being 30 years younger than them and only having 15 years experience with FDA matters, advised them that the FDA was highly unlikely to agree with them, they, of course due to their superior resumes and multiple PhDs, dismissed my advice as naive and overly conservative. 6 months later, FDA informed them that the compound of a drug and a GRAS component is not automatically approved for the same uses as the drug alone.

    --
    Україна не входить до складу Росії.
    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2